ArticleNPJ vaccines2025
Evaluation of highly conserved Burkholderia pseudomallei outer membrane proteins as protective antigens against respiratory melioidosis.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Antibodies toMicroorganisms · 2026Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
Burkholderia pseudomallei (Bpm), the etiological agent of melioidosis, lacks approved vaccines. However, several candidates have demonstrated protection in animal models. Interestingly, some of these vaccines can induce cross-protective immunity against the closely related species B. mallei. This led us to search the Bpm proteome for antigens that are highly conserved in more distantly related pathogenic Burkholderia species, which could potentially serve as components of a pan-Burkholderia vaccine. We identified three proteins, OmpA1, OmpA2, and Pal, which were coupled to an immunogenic gold nanoparticle (AuNP) platform. Intranasal immunization with these vaccines resulted in the induction of robust Th1/Th2-balanced responses and mucosal immunity, and the AuNP-OmpA1 and AuNP-OmpA2 vaccinated animals were significantly protected from a lethal Bpm respiratory challenge. Serum antibodies were highly cross-reactive to B. mallei and partially cross-reactive to B. multivorans and B. cenocepacia, indicating that the antigens contain highly conserved epitopes that can be incorporated in a pan-Burkholderia vaccine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.